The evolving paradigm of organoids: advances in cell line-derived organoids with 3-dimensional printing and emerging technologies

Organoid research has rapidly emerged as a prominent field within the life sciences, particularly in biomedical research. Stem cells represent the primary source of human organoids due to their exceptional ability to reproduce organ-specific functions and differentiation pathways. Organoids derived from pluripotent stem cells or other stem cells have proven to be powerful platforms for studying developmental biology, disease mechanisms, and therapeutic responses. Nonetheless, stem cell-derived organoids face several critical limitations, including batch-to-batch variability, lengthy maturation periods, and ethical concerns—particularly with the use of embryonic stem cells. In response to these challenges, alternative approaches have gained attention, especially the generation of organoids from established cell lines. Organoids derived from immortalized or cancer cell lines present distinct advantages, including greater genetic stability, rapid expansion, reproducibility, and scalability. These features make them particularly suitable for high-throughput applications such as toxicological screening and drug discovery. Furthermore, recent technological advancements—including 3-dimensional bioprinting, microfluidic systems, and co-culture platforms—have enhanced the architectural fidelity and functional complexity of cell line-derived organoids. Such innovations are driving the evolution of organoid platforms beyond conventional stem cell models. Ultimately, the full translational potential of cell line-derived organoids in both preclinical and clinical contexts will depend on the establishment of standardized experimental protocols and consistent regulatory frameworks.